GREENWICH LIFESCIENCES INC (GLSI) Stock Price & Overview
NASDAQ:GLSI • US3968791083
The current stock price of GLSI is 26.94 USD. Today GLSI is up by 4.58%. In the past month the price decreased by -9.38%. In the past year, price increased by 124.5%.
GLSI Key Statistics
- Market Cap
- 373.119M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.46
- Dividend Yield
- N/A
GLSI Stock Performance
GLSI Stock Chart
GLSI Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to GLSI. When comparing the yearly performance of all stocks, GLSI is one of the better performing stocks in the market, outperforming 98.03% of all stocks.
GLSI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GLSI. No worries on liquidiy or solvency for GLSI as it has an excellent financial health rating, but there are worries on the profitability.
GLSI Earnings
GLSI Forecast & Estimates
8 analysts have analysed GLSI and the average price target is 48.45 USD. This implies a price increase of 79.84% is expected in the next year compared to the current price of 26.94.
GLSI Groups
Sector & Classification
GLSI Financial Highlights
Over the last trailing twelve months GLSI reported a non-GAAP Earnings per Share(EPS) of -1.46. The EPS decreased by -82.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -511.58% | ||
| ROE | -891.34% | ||
| Debt/Equity | 0 |
GLSI Ownership
GLSI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.3 | 401.392B | ||
| AMGN | AMGEN INC | 16.45 | 202.383B | ||
| GILD | GILEAD SCIENCES INC | 16.81 | 184.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.75 | 126.804B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.51 | 81.619B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.21 | 42.754B | ||
| INSM | INSMED INC | N/A | 31.007B | ||
| NTRA | NATERA INC | N/A | 28.197B | ||
| BIIB | BIOGEN INC | 11.72 | 27.651B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.94 | 23.485B | ||
| MRNA | MODERNA INC | N/A | 21.714B | ||
| EXAS | EXACT SCIENCES CORP | 340.08 | 19.732B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.591B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GLSI
Company Profile
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 4 full-time employees. The company went IPO on 2020-09-25. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. The company has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.
Company Info
IPO: 2020-09-25
GREENWICH LIFESCIENCES INC
3992 Bluebonnet Dr, Building 14
Stafford Texas TEXAS 33954 US
CEO: Snehal Patel
Employees: 4
Phone: 12034343290
GREENWICH LIFESCIENCES INC / GLSI FAQ
What does GLSI do?
Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 4 full-time employees. The company went IPO on 2020-09-25. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. The company has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.
Can you provide the latest stock price for GREENWICH LIFESCIENCES INC?
The current stock price of GLSI is 26.94 USD. The price increased by 4.58% in the last trading session.
Does GLSI stock pay dividends?
GLSI does not pay a dividend.
What is the ChartMill technical and fundamental rating of GLSI stock?
GLSI has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is GLSI stock listed?
GLSI stock is listed on the Nasdaq exchange.
Can you provide the market cap for GREENWICH LIFESCIENCES INC?
GREENWICH LIFESCIENCES INC (GLSI) has a market capitalization of 373.12M USD. This makes GLSI a Small Cap stock.
When does GREENWICH LIFESCIENCES INC (GLSI) report earnings?
GREENWICH LIFESCIENCES INC (GLSI) will report earnings on 2026-04-13.